Rua Bioscience Limited (RUA.NZ)
NZD 0.03
(0.0%)
NZD 0.03
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 973.12 Thousand NZD | 17.2% |
| 2023 | 830.3 Thousand NZD | -91.14% |
| 2022 | 9.37 Million NZD | 332.52% |
| 2021 | 2.16 Million NZD | 63.58% |
| 2020 | 1.32 Million NZD | 113.2% |
| 2019 | 621.56 Thousand NZD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 973.12 Thousand NZD | 17.2% |
| 2024 Q1 | 554.63 Thousand NZD | -33.2% |
| 2024 Q4 | 973.12 Thousand NZD | 0.0% |
| 2024 Q2 | 554.63 Thousand NZD | 0.0% |
| 2023 Q3 | 830.3 Thousand NZD | -65.34% |
| 2023 Q1 | 2.39 Million NZD | -74.45% |
| 2023 Q4 | 830.3 Thousand NZD | 0.0% |
| 2023 FY | 830.3 Thousand NZD | -91.14% |
| 2023 Q2 | 2.39 Million NZD | 0.0% |
| 2022 Q1 | 1.56 Million NZD | -27.65% |
| 2022 FY | 9.37 Million NZD | 332.52% |
| 2022 Q4 | 9.37 Million NZD | 0.0% |
| 2022 Q3 | 9.37 Million NZD | 497.79% |
| 2022 Q2 | 1.56 Million NZD | 0.0% |
| 2021 Q1 | 1.26 Million NZD | -7.97% |
| 2021 Q3 | 2.01 Million NZD | 60.0% |
| 2021 Q4 | 2.16 Million NZD | 7.45% |
| 2021 Q2 | 1.26 Million NZD | 0.0% |
| 2021 FY | 2.16 Million NZD | 63.58% |
| 2020 FY | 1.32 Million NZD | 113.2% |
| 2020 Q4 | 1.37 Million NZD | 3.4% |
| 2020 Q3 | 1.32 Million NZD | 0.0% |
| 2020 Q1 | - NZD | 0.0% |
| 2019 FY | 621.56 Thousand NZD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AFT Pharmaceuticals Limited | 77.46 Million NZD | 98.744% |
| Greenfern Industries Limited | 1.28 Million NZD | 24.257% |